Analytics, Bioanalytics & CMC (Chemistry, Manufacturing, and Controls) group supports the analytical and bioanalytical characterization of newly discovered targets and therapeutics for all research and early development programs at 23andMe. Our group utilizes various state-of-art technologies (e.g. LC-MS, HPLC, cIEF, MSD and etc.) to thoroughly assess the developability of therapeutic candidates, to perform bioanalytical assays (e.g. Biomarker, PK, ADA) and to collaboratively develop CMC strategies for the lead molecule.
Hee Joo completed his Ph.D. at University of Hawaii where he studied antibody engineering and hapten chemistry focused on immunoassay development for small molecules for rapid assessment of environmental contamination and human exposure to pesticides.
At 23andMe, she focuses on characterizing the product quality and attributes using a variety of methods like mass spectrometry, size exclusion chromatography, charge profiling, and glycan profiling. Prior to joining 23andMe, Navneet worked in the Analytical development groups at biopharma companies like NGM Bio and Merck Serono. Navneet received her B.S in Biomedical Engineering from the University of Michigan, Ann Arbor.
The Antibody and Protein Engineering team consists of biologists, immunologists, structural biologists, and protein engineers. We design, engineer, and produce high quality therapeutic proteins to support target discovery and validation. We also focus our efforts on antibody discovery. We utilize a variety of techniques (e.g. hybridoma and phage display) to obtain antibody candidates as therapeutics or critical reagents. We study whether these discovered antibodies perform a desired function and often further engineer them to optimize their functions. We enable testing of our improved molecules by closely collaborating with Biology, Analytics as well as late stage Drug Development groups. We aim to deliver drug candidates based on their efficacy, potency, and safety to treat unmet medical needs.
Before joining 23andMe Patrick worked as Senior Scientist at Abbvie Stemcentrx where he focused on the discovery and engineering of antibody drug conjugates as cancer therapeutics. Patrick completed his postdoctoral training at Genentech in the department of Antibody Engineering. He earned his Ph.D from the University of Heidelberg in Germany.
Before joining 23andMe Shashank worked as a Senior Scientific Researcher for another company Affinita Biotech. That work included leveraging antibody engineering to develop novel cancer therapeutics. Prior to his job in biotech, Shashank completed his postdoctoral training in the lab of Ehud Isacoff at UC Berkeley’s Molecular and Cellular Biology department, where he mainly focused on delineating the molecular mechanism of multimerization in the activation of epidermal growth factor receptor (EGFR). Shashank earned his Ph.D. from UNT Health Science Center, Tx and his M.S. from Sardar Patel University, Gujarat, India where he also earned his undergraduate degree in Biotechnology.
This team applies computational methods to drug target identification and indication selection, as well as to the analysis of target biology and drug mechanism of action. We perform integrative analyses of data from 23andMe’s Research platform, functional genomics experiments, and other experiments performed in the Therapeutics labs to guide decisions to initiate and advance drug development projects.
Steven came to 23andMe from Pfizer where he worked on an interdisciplinary team that combined computational biology and Next Generation Sequencing both for target discovery and for antibody engineering. That work included computational data analysis, and the implementation of laboratory information systems.
Before his time at Pfizer, Steven worked for Perlegen Sciences. At Perlegen he was a member of the computational design team that developed custom high-density genotyping arrays for genetic association studies as well as exome capture methods for early NGS studies of rare variants. Early in his career, Steven worked at Incyte Genomics, where he worked on computational annotation of human protein coding genes during the lead up to the completion of the Human Genome Project.
Steven received his undergraduate degree in Chemistry from the University of Chicago, and his Ph.D., also in Chemistry from Stanford University.
Prior to 23andMe, Vladimir was one of the founding scientists at the New York Genome Center, where as a Manager of Computational Biology he lead a cancer genome analysis and computational biology group and actively contributed to the Center’s growth from a 20- to a 150-person organization.
Vladimir interned in the Personalized Healthcare group at Siemens Corporate Research, and at the Center for Computational Biology and Bioinformatics at the Indiana University School of Medicine.
Vladimir earned a Ph.D. in Computer Science from the University of California at Riverside, specializing in computational biology. He trained as postdoctoral research scientist at Columbia University and a postdoctoral fellow at Cold Spring Harbor Laboratory, both in computational genetics. Vladimir has co-authored 35 publications and 2 patents.
The Development Sciences group bridges the discovery of new drug targets and the evaluation of these drugs in humans. We analyze and interpret biological samples derived from blood and tissues to understand pharmacokinetics and pharmacodynamics of therapeutic drug candidates. In addition, we use a variety of models to predict and evaluate the likely activity and side effects of our therapeutic candidates throughout the lifecycle of research and drug development.
The Development group evaluates drugs that are proposed to enter clinical trials and ensures that the regulatory requirements and the highest ethical and clinical standards are met when conducting clinical trials. We use human genetics, tissue and blood biomarkers, in order to bring the right drugs to the right patients. We develop drugs with high unmet clinical need into clinical trials with the goal of obtaining worldwide marketing approvals as rapidly and efficiently as possible, in order to get drugs to the patients who need them as quickly as we can.
Jennifer has considerable drug development experience and has most recently worked as a consultant and advisor to biotech CEOs and investors on their drug development strategies. She has been the Chief Medical Officer and Executive Vice President of Research and Development at Loxo Oncology where she oversaw the clinical development of Vitrakvi (Trk inhibitor). Prior to that she was a Senior Group Director at Genentech, a member of the Roche Group, where she oversaw the Erivedge (hedgehog), Zelboraf (b-RAF), and Cotellic (mek) clinical development programs among many others.
She received her undergraduate degree from Caltech, her MD and PhD degrees from Georgetown, and completed her internal medicine residency at the University of California Davis, her medical oncology fellowship at the National Cancer Institute, and was a Senior Investigator at the Cancer Therapeutics Evaluation Program at NCI and an attending physician in breast cancer at the National Institutes of Health and the National Naval Medical Center in Bethesda. She has co-authored papers appearing in the New England Journal of Medicine, Science, Cancer Discovery, Journal of Clinical Oncology, and Nature Reviews Cancer.
Adrian was nurtured into a physician-scientist over a thirteen year period at Genentech, where he contributed to multiple programs in oncology, angiogenesis and neuroscience. Most recently he was the Chief Medical Officer at Immune-Onc Therapeutics, developing novel immunotherapy checkpoint inhibitor for cancer patients. Prior to that, Adrian served as a Vice President and Head of Early Development at Achaogen where he led numerous development functions and played a leading role in the development and FDA approval of ZEMDRI for the treatment of serious multi-drug resistant infections.
Adrian holds an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree, with honors, from the Faculty of Medicine and Health at the University of Leeds, United Kingdom. His scientific training was conducted in the research laboratories of Genentech, leading to the award of a Ph.D. through the University of Leeds. Adrian is also a Fellow of the Royal College of Pathologists (F.R.C.Path.), having completed joint clinical and academic postgraduate training at the Oxford Deanery and the University of Oxford, United Kingdom. Following his training, Dr. Jubb was appointed to a faculty position in the Nuffield Department of Clinical Laboratory Sciences, University of Oxford, where he led several projects in the fields of angiogenesis and oncology as a principal investigator. Adrian has authored over 55 scientific publications, including numerous papers in top-tier journals and is a named inventor on 4 issued patents.
Dylan came to 23andMe after beginning his career in the Formulation Process Development group at Gilead Sciences, where he made contributions to programs in discovery, clinical development, and commercial launch, including authoring the drug product commercial control strategy for the filgotinib NDA submitted in 2019. Dylan received his PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill and BS in Chemical and Biological Engineering from the University of Colorado at Boulder.
Prior to 23andMe, Sophia spent 4 years working in the Department of Clinical Pharmacology at Gilead Sciences where she contributed to programs across the drug development spectrum. She contributed to the development of early and late stage compounds within the antiviral and liver disease therapeutic areas. She contributed to the global approvals of Gilead’s Tenofovir Alafenamide-containing fixed-dose combinations for HIV treatment and prevention and for Hepatitis B in adults and pediatric patients. She also led the clinical pharmacology strategy that was pivotal to the acceleration of pediatric development of drugs in Gilead’s HIV and Hepatitis B portfolios.
Before her foray in the pharmaceutical industry, Sophia worked as a pharmacist, serving Bay area communities in San Francisco, the East, North and South Bay.
Sophia received a PharmD and PhD in Pharmaceutical Sciences and Pharmacogenomics from the University of California, San Francisco and a BS in Molecular and Cell Biology from Cornell University in Ithaca, NY.
The Portfolio Management and Operations (PM&O) team is responsible for the program management of our therapeutics portfolio and the operations of our overall Therapeutics organization. In particular, the PM&O team leads portfolio planning, therapeutic project management, early stage commercial and competitive assessments and the operations of the 100+ employee Therapeutics organization. In addition, the PM&O team leads alliance management and program management for the Therapeutics external collaborations.
She worked at Gilead for 18 years. During her tenure at Gilead, she developed and maintained the most important and complex alliance collaborations. She was involved in the development of several drugs at Gilead, including TRUVADA, ATRIPLA, STRIBILD and GENVOYA. Monica participated in several business development transactions, including in-licensing and partnerships with Japan Tobacco, ONO Pharmaceuticals and Galapagos. Prior to joining Gilead, Monica worked at Schering-Plough and GSK.
Monica received her degree in Chemistry and Pharmaceutical Technologies at the University of Milan.
Before joining 23andMe, Maithili worked as a project manager at an early-stage biopharmaceutical startup where she wore multiple hats and provided cross-functional scientific and business support. Prior to working in the startup, Maithili was a Project Architect at PreScouter where she managed teams working on consulting projects with industry clients. She has also advised on market research projects at the Office for Technology Development at UT Southwestern.
Maithili earned her Ph.D. in Cancer Biology from UT Southwestern Medical Center in Dallas, TX, where her research focused on identifying new therapies for targeting chemotherapy-resistant lung cancers. In addition, she has an M.S. in Biotechnology from the Institute of Bioinformatics & Biotechnology, Pune, India. Her scientific background is complemented with business foundations from Harvard Business School CORe.
Over the years, Krista has worked across the value stream at a number of the international biotechnology companies including: Genentech, Roche, Gilead, Abbott Labs. Her previous global roles include: Project Manager, Process Manager, Resource Manager, Global Portfolio Analyst, Business Systems Analyst, and Business Operations Leader.
Krista earned a BS in Biochemistry from UW-Madison.
Our group uses the 23andMe research platform to identify genes that could potentially express novel protein drug targets. These drug targets can be used to create therapies for treating patients with high unmet medical needs. The group works closely with the computational biologists and statistical geneticists in the Research Team to analyze genome-wide association study (GWAS) data. We work closely with biologists in the Therapeutics group to evaluate various target properties and to develop target validation plans. The group oversees the development of new drug discovery project proposals, contributes to biological experiments to support target validation, and leads preclinical drug discovery programs.
The Biology group consists of scientists with expertise in immunology, oncology, cardiovascular disease, and metabolic disease. The group is tasked with multiple responsibilities, from discovery and evaluation of new drug targets to testing potential therapeutics for biological activity in the appropriate disease pathways. We design and perform a wide range of biological studies to progress our therapeutic programs from early stage research towards clinical development. Our target evaluation work is carried out in concert with the Target Discovery team where we leverage our biological expertise to complement the genetic analyses coming from our colleagues in the Research Team.
In roles prior to joining 23andMe, Bill was recently Chief Scientific Officer at ProNeurotech (now Nura Bio). From 1996 to 2019, Bill held various positions of increasing responsibility at Amgen culminating as Executive Director Research. At Amgen Bill and his teams contributed to the pre clinical development of numerous molecules, including Sensipar, Parsibiv, Evenity, Olpasiran, AMG 594 and AMG 609. Also, at Amgen Bill worked closely with the team at deCODE genetics to identify and advance genetically validated therapeutic targets. Bill received his Ph.D. in Genetics from SUNY-Stony Brook and conducted postdoctoral research at the Oak Ridge National Labs. Additionally, Bill has co-authored numerous publications and is co-inventor of many patents.
Prior to joining 23andMe, Antony was at Amgen for 13 years in the Inflammation and Oncology Therapeutic Area where he provided leadership in new target discovery strategies, and led drug discovery programs through preclinical development for autoimmune diseases and cancer immunotherapy. He has expertise in small molecule, antibody, and protein therapeutic drug development. His research focused on understanding cytokine biology from receptor engagement to downstream signaling events and consequent changes in immune cell function.
Antony received his D.Phil. in Immunology from the University of Oxford, UK, and was a post-doctoral research fellow at Janssen, San Diego, and the MRC National Institute for Medical Research, London, UK.
She then worked in NGM Biopharmaceutics in South San Francisco for 5 years developing biologics drugs for cardiometabolic diseases. She joined 23andMe in July 2015 as the 4th founding member of the newly formed therapeutics group aiming to leverage 23andMe’s human genetic data towards drug discovery.
Prior to coming to 23andMe Davide spent a decade at Pfizer’s Rinat Laboratories in South San Francisco as a Principal Scientist and Associate Research Fellow. Before that he was among the first Scientists to work at Rinat Neuroscience Corporation in Palo Alto.
Davide received a Ph.D. in biochemistry from the Swiss Federal Institute of Technology in Zurich (ETH). He also has an MS in biochemistry from ETH. His postdoctoral work was done at Stanford University School of Medicine’s Department of Molecular and Cellular Physiology where Dr. Richard Scheller was his advisor.
Prior to 23andMe, Jen was the liver team project lead at Surrozen, using antibody therapeutics to leverage the Wnt pathway for regenerative medicine. Jen earned her Ph.D. in Helen Blau’s lab at Stanford University as an NSF graduate research fellow studying mechanisms of DNA methylation and nuclear reprogramming. She completed her NIH F32 post-doctoral studies with Monte Winslow in the Genetics department at Stanford University using genetically engineered mouse models to elucidate mechanisms of lung cancer metastasis. Jen has authored over 15 publications spanning plant pathology, virology, stem cell biology, oncology and regenerative medicine, including first-author publications in Nature and Cancer Cell. She is an inventor on 2 patents.
As a graduate student in Erin Adams’ lab at the University of Chicago, Louise studied the molecular basis of self and foreign lipid antigen presentation and recognition by the human immune system. Louise has co-authored over 20 peer reviewed publications and is an inventor on 5 patents.
Kristie also serves on the team evaluating genetic data for the purpose of drug discovery and target evaluation. Prior to coming to 23andMe, Kristie’s academic and postdoctoral work focused on translational research with the potential to impact human health.
During her postdoctoral studies at the University of California, Berkeley, she was a member of an international collaboration studying anti-dengue human antibodies for vaccine development and therapeutic use. Additional research projects sought to determine the potential of using immunomodulatory agents to treat dengue fever. Kristie received her Ph.D. in Molecular Microbiology from the University of Texas Southwestern Medical Center at Dallas, where she conducted medically relevant studies with Hepatitis C Virus (HCV) and identified a mechanism of host-based drug resistance that correlated with treatment outcome in HCV patients undergoing therapy.
In Genentech’s discovery immunology department, she worked on understanding the biology of potential drug targets in the context of lupus and inflammatory bowel disease. During her postdoctoral studies at the University of California, San Francisco in Mark Anderson’s lab, she helped demonstrate that manipulating central tolerance can promote anti-tumor immune responses. Maria received her Ph.D. in Molecular and Cell Biology from the University of California, Berkeley in Greg Barton’s lab where she studied how dysregulation of TLR9 can lead to autoinflammation in vivo.
Before joining 23andMe, Ria was a postdoctoral scholar at Stanford University, where she studied the underlying mechanism of ligand-gated activation of the oncoprotein Smoothened. As a graduate student, she used X-ray crystallography and pulsed dipolar ESR spectroscopy to elucidate the architecture of bacterial flagellar rotor.
Ria earned her Ph.D. in Biochemistry from Cornell University. In addition she has an M.S. in Chemistry from the Indian Institute of Technology, Kanpur and a B.S. in Chemistry from the University of Calcutta, India.
Prior to joining 23andMe, Tina worked at a next-generation sequencing start up company called Eve Biomedical, where she bioconjugated and studied various polymerases for microfluidic-based assays. Prior to that, she worked at Maxygen/Perseid (a subsidiary of Astellas Pharma) in the Molecular Biology department, where she used phage display techniques to help discover immunomodulatory protein therapeutics.
Tina earned her M.S. in Biomedical Engineering from Columbia University. She also has her B.S. in Bioengineering from the University of California, Berkeley.
Ashka joined the Therapeutics team in 2017 from Genentech where she helped to develop receptor discovery technologies aimed to identify novel therapeutic targets.
Lino received his B.S. in Chemistry from the University of California, Santa Barbara and completed his Ph.D. at the University of California, Berkeley, where he studied the structural specificity of protein interactions. Lino did a postdoctoral fellowship at Stanford focusing on the structures and biochemical properties of neuronal membrane proteins involved in
Lino has published over 30 peer reviewed scientific and review articles, which have garnered over 3K citations. In addition to his research, Lino has been a strong proponent for broadening participation in the STEM workforce. For his contributions, Lino was recognized with a Genentech Diversity Champion corporate award in 2005. Lino also is a past-president of the Society for Advancement of Hispanics/Chicanos and Native Americans in Science (SACNAS).
Prior to joining 23andMe, Patrick spent nine years at Amgen leading a functional genomics group that built and employed arrayed and pooled genomic perturbation platforms for target identification, mechanism of action and biomarker identification studies across multiple therapeutic areas. Patrick moved to Amgen after three years at SwitchGear Genomics leading functional genomics efforts in collaboration with a number of Encyclopedia of DNA Elements (ENCODE)-funded labs and developing new products and applications.
Patrick received his Ph.D. in Genetics from Stanford University and his B.A. in Biology from Pomona College.
Prior to joining 23andMe, Joel worked at a medical device start-up company called Pulse Biosciences, where he worked to use Nano Pulse Stimulation technology in combination with other IO therapies as an in situ cancer vaccine as well as develop and execute in vivo and in vitro immune assays.